Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: A clinical-stage medical device company focused on bone regeneration in spinal fusion using the recombinant human protein NELL-1 combined with demineralized bone matrix (DBM). The lead product, NB1, is currently in a pilot clinical study in Australia. The Company has no significant operating history and has incurred accumulated losses of approximately $86.0 million since inception.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,017,092) | $(865,970) |
| Loss Per Share (Basic & Diluted) | $(0.32) | $(1.31) |
| Operating Expenses | $1,038,486 | $903,536 |
| Research & Development | $423,576 | $245,625 |
| General & Administrative | $614,910 | $657,911 |
| Cash and Cash Equivalents (End of Period) | $2,746,555 | $3,227,634 |
| Net Cash Used in Operating Activities | $(926,125) | $(1,303,411) |
| Net Cash Provided by Financing Activities | $347,549 | $1,504,476 |
| Total Assets | $3,162,060 | $3,861,369 |
| Total Liabilities | $251,158 | $377,712 |
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 17.5% to $1.02 million, driven primarily by higher R&D expenses.
- R&D Expenses: Increased by 72.5% ($177,951) due to formulation processes completed with Contract Development and Manufacturing Organizations (CDMOs) in preparation for future pivotal studies.
- G&A Expenses: Decreased by 6.5% ($43,001) compared to the prior year.
- Interest Income: Increased significantly to $20,039 from $255, reflecting higher yields on cash balances.
- Warrant Liability: The change in fair value of warrant liability decreased to a gain of $1,355 from $37,311 in the prior year.
- Capital Raise: The Company raised $347,549 net proceeds through its At-The-Market (ATM) offering program, selling 317,060 shares.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: The Company has substantial doubt about its ability to continue as a going concern. With $2.75 million in cash, management estimates operations can be funded into the fourth quarter of 2025. Operating expenditures for the next 12 months are estimated at $4.9 million. Additional financing is required to continue operations.
- Nasdaq Listing Deficiency: On April 7, 2025, the Company received notice from Nasdaq that it failed to maintain the minimum $1.00 bid price for 30 consecutive days. The Company has 180 days (until October 6, 2025) to regain compliance. Failure to do so may result in delisting.
- Reverse Stock Split: Management intends to seek stockholder approval for a reverse stock split (range of 1-for-2.5 to 1-for-10) at the Annual Meeting on May 30, 2025, to regain compliance with Nasdaq listing rules.
- Clinical Progress: The pilot clinical study for NB1 in Australia is ongoing. The Company triggered a $100,000 milestone payment to UCLA TDG in 2024 upon enrolling the first subject.
- Risks: Risks include the inability to raise additional capital, potential delisting from Nasdaq, failure of clinical trials, and regulatory hurdles for FDA Pre-Market Approval (PMA).
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $4.9 million operating expenditure estimate and the timeline for funding into Q4 2025.
- Reverse Stock Split Approval: Monitor the outcome of the May 30, 2025, Annual Meeting regarding the reverse stock split proposal.
- Nasdaq Compliance: Track the stock price to ensure it meets the $1.00 bid price requirement for 10 consecutive days within the 180-day compliance window.
- Capital Raising: Assess the Company's ability to secure debt or equity financing before cash reserves are depleted.
- Clinical Trial Status: Review updates on the NB1 pilot study in Australia and any potential delays or adverse events.